Tezepelumab in Severe asthma: NCT07363642 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Recruiting
Recruitment status
400
Planned enrollment
2028-02-07
Primary-completion proxy
Executive view
NCT07363642 evaluates Tezepelumab in Severe asthma. The disclosed sponsor is AstraZeneca PLC, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control, assessed over within 36 weeks after the first administration.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07363642 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Severe asthma landscape. Drug & Asset MCP drug_fetch was queried for Tezepelumab, while Company & Deal Intelligence MCP organization_fetch was queried for AstraZeneca PLC.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07363642 | Tezepelumab | Phase 3 / Recruiting | AstraZeneca PLC | China | To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in… within 36 weeks after the first administration | 2028-02-07 |
| NCT07359846 | GB-0895 | Phase 3 / Recruiting | Generate Biomedicines, Inc. | Argentina, United States, Japan, Ukraine, United Kingdom, Spain, Belgium, Turkey, Italy, Slovakia, Serbia, France, Australia, Estonia | To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52 | 2029-01-01 |
| NCT07343661 | Mepolizumab | Phase 4 / Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | Italy | Saliva, sputum, and plasma proteomic profile of EGPA patients From the data to the enrollment until the end of the study, up to 52… | 2026-10-17 |
| NCT07276724 | GB-0895 | Phase 3 / Recruiting | Generate Biomedicines, Inc. | Greece, Netherlands, Latvia, Romania, Hungary, Czechia, United States, South Africa, Bulgaria, Portugal, Germany | To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52 | 2028-12-01 |
| NCT07013123 | Tezepelumab | Phase 3 / Not yet recruiting | University Hospital of Montpellier | Geography not reported | Annualized total number of asthma exacerbations under acarizax/placebo treatment Between Day 0 and Month 18 | 2029-08-18 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07363642 is a Phase 3, recruiting study with 400 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control” over “within 36 weeks after the first administration.” The retrieved endpoint description is: Main Endpoints: Proportion of patients with at least one controller medication category reduction at the end of reduction phase (week 36) while sustaining asthma control * discontinuation of LTRA, or * discontinuation of LAMA, or * discontinuation of theophylline, or * Reduce inhale therapy to MD ICS/LABA, or * Reduce inhale therapy to LD ICS/LABA.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 400 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Severe asthma. These records do not establish direct evidence for NCT07363642 unless the registration number matches.
Tezepelumab in the Framework of Use in Special Situations Before Commercialization: T-ROSS, a Retrospective Real-world Study in Spain
Not Applicable; n=33; clinical remission = 13.8 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42002456/
B32-32 Evolution in the Use of Biologics Among US Adults With Severe Asthma: Data From the CHRONICLE Study
Not Applicable; n=4366; Biologic initiation(From December 2021 to February 2025) = 31.1 % ; Biologic initiation(From December 2021 to February 2025) = 33.2 % Source: https://academic-oup-com.libproxy1.nus.edu.sg/ajrccm/article/212/Supplement_1/aamag162.472/8679419
A36-12 The Asthma Treatment Paradox: High Steroids, Low Controllers, and Fewer Biologics
Not Applicable; n=740; Biologic therapy utilization = 11.3 % Source: https://academic-oup-com.libproxy1.nus.edu.sg/ajrccm/article/212/Supplement_1/aamag162.339/8679805
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Tezepelumab is indexed as Monoclonal antibody with TSLP biology and a global stage of Approved. The asset profile lists AstraZeneca AB as an originator or developer.
AstraZeneca PLC is indexed in United Kingdom with the website http://www.astrazeneca.com. AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. The record lists 352 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Tezepelumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07363642
Protocol source: https://clinicaltrials.gov/study/NCT07363642
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Tezepelumab in Severe asthma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control and 2028-02-07 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
